These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
213 related items for PubMed ID: 17062919
21. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Zhu S, Liu Y, Wang L, Meng QH. Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891 [Abstract] [Full Text] [Related]
22. A comparison of valsartan and perindopril in the treatment of essential hypertension in the malaysian population. Bavanandan S, Morad Z, Ismail O, Chandran A, Thayaparan T, Singaraveloo M. Med J Malaysia; 2005 Jun; 60(2):158-62. PubMed ID: 16114156 [Abstract] [Full Text] [Related]
25. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E. J Pharmacol Exp Ther; 2004 Dec; 311(3):989-95. PubMed ID: 15302895 [Abstract] [Full Text] [Related]
26. [Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study]. Rodríguez Pérez JC, Novoa Novoa J, Caballero A, Anabitarte A, Plaza C, Palop L, Rodríguez Esparragón F. Nefrologia; 2005 Dec; 25(5):500-8. PubMed ID: 16392299 [Abstract] [Full Text] [Related]
28. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097 [Abstract] [Full Text] [Related]
29. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. Liu L, Zhao SP, Zhou HN, Li QZ, Li JX. J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915 [Abstract] [Full Text] [Related]
30. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Lacourcière Y, Wright JT, Samuel R, Zappe D, Purkayastha D, Black HR, EVALUATE study. Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192 [Abstract] [Full Text] [Related]
31. Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients. Durmus A, Dogan E, Erkoc R, Sayarlioglu H, Topal C, Dilek I. Int J Clin Pract; 2005 Sep; 59(9):1001-4. PubMed ID: 16115171 [Abstract] [Full Text] [Related]
32. Monocyte chemoattractant protein-1 or macrophage inflammatory protein-1alpha deficiency does not affect angiotensin II-induced intimal hyperplasia in carotid artery ligation model. Zhang LN, da Cunha V, Martin-McNulty B, Rutledge J, Vergona R, Sullivan ME, Wang YX. Cardiovasc Pathol; 2007 Sep; 16(4):231-6. PubMed ID: 17637431 [Abstract] [Full Text] [Related]
33. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P, Santoro T, Preti P, Mugellini A. Am J Hypertens; 2008 Sep; 21(9):1034-9. PubMed ID: 18566593 [Abstract] [Full Text] [Related]
34. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial. Conen D, Everett BM, Glynn RJ, Ridker PM. Heart; 2008 Mar; 94(3):e13. PubMed ID: 17923463 [Abstract] [Full Text] [Related]
35. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I. Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820 [Abstract] [Full Text] [Related]
36. Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension. Minami J, Ohno E, Furukata S, Ishimitsu T, Matsuoka H. J Hum Hypertens; 2009 Oct; 23(10):683-6. PubMed ID: 19369955 [No Abstract] [Full Text] [Related]
38. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Serebruany VL, Pokov AN, Malinin AI, O'Connor C, Bhatt DL, Tanguay JF, Sane DC, Hennekens CH. Am Heart J; 2006 Jan; 151(1):92-9. PubMed ID: 16368298 [Abstract] [Full Text] [Related]
39. [Effects of angiotensin II on inflammation mediators in healthy subjects]. Lottermoser K, Ulrich-Merzenich G, Vetter H, Düsing R. Dtsch Med Wochenschr; 2003 Nov 21; 128(47):2470-5. PubMed ID: 14628252 [Abstract] [Full Text] [Related]
40. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Saisho Y, Komiya N, Hirose H. Diabetes Res Clin Pract; 2006 Nov 21; 74(2):201-3. PubMed ID: 16737758 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]